China Renews List of Devices Exempt From Clinical Trials
This article was originally published in Clinica
Executive Summary
China's Food and Drug Administration is inviting feedback on a new batch of medium- and high-risk medical devices that it intends to exempt from having to undergo local clinical trials. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market.
You may also be interested in...
China Confirms Second Batch Of Device Clinical Trial Exemptions
Chinese regulators have added another 359 medical devices to the list of those not needing to undergo clinical investigation in China following feedback from the industry. This second batch of exemptions follows the initial list issued at the end of 2014.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.